Spotlight: R&D productivity and R&D profitability are related—but they are not the same.
Pharma and MedTech organizations are rightly focused on faster development, shorter cycle times, better resource utilization, and higher probabilities of technical and clinical success. But greater efficiency does not automatically create better returns.
The bigger leadership question is: Are R&D productivity initiatives actually improving the economics of the portfolio?
In this post, I explore why R&D performance needs to connect execution with portfolio strategy, development economics, differentiation, commercial potential, and resource allocation—and why the goal should be to make R&D not just more productive, but a better-performing investment.
Checkout the full post below…
#Pharma #MedTech #RDStrategy #PortfolioStrategy #Innovation #LifeSciences
Pharma and MedTech organizations are rightly focused on faster development, shorter cycle times, better resource utilization, and higher probabilities of technical and clinical success. But greater efficiency does not automatically create better returns.
The bigger leadership question is: Are R&D productivity initiatives actually improving the economics of the portfolio?
In this post, I explore why R&D performance needs to connect execution with portfolio strategy, development economics, differentiation, commercial potential, and resource allocation—and why the goal should be to make R&D not just more productive, but a better-performing investment.
Checkout the full post below…
#Pharma #MedTech #RDStrategy #PortfolioStrategy #Innovation #LifeSciences
There is a lot of focus across Pharma and MedTech on improving R&D productivity.
Faster development. Better use of resources. Shorter cycle times. Higher technical and clinical success rates. More efficient trials. More disciplined execution.
All of these matter. But I think there is a broader question leadership teams need to ask: Are we improving R&D productivity—or are we improving the economics of R&D? The two are related, but they are not the same.
A R&D organization can become more productive and still struggle to generate attractive returns from its innovation/ research investments. Why? Because R&D profitability depends on more than how efficiently a program moves through development.
It depends on:
A program delivered faster and at lower cost is certainly more productive. But if it addresses a limited opportunity, enters an increasingly crowded market, lacks meaningful differentiation, or requires disproportionate downstream investment, greater development efficiency may not translate into greater economic value. That distinction matters...
For executive teams, the conversation therefore needs to move beyond “How do we make R&D more efficient?” to “How do we make R&D a better-performing investment?”
That requires connecting decisions that are often managed separately: portfolio strategy, development economics, evidence generation, resource allocation, product differentiation, and commercial potential.
The objective should not be productivity or profitability. It should be a R&D system where better science, better execution, and better investment decisions reinforce one another.
For Pharma and MedTech leaders facing increasing pressure on innovation returns, I believe this distinction is becoming increasingly important.
Improving how R&D operates is valuable. Improving the return on what R&D invests in is ultimately what creates enterprise value.
For leadership teams examining R&D performance, this may be a useful place to start: Are your productivity initiatives actually changing the economics of the portfolio? Is your R&D organization becoming more efficient—or is it also becoming a better-performing investment?
I work on questions at the intersection of R&D strategy, portfolio economics, and operating performance. Let’s discuss how these can work together to improve your R&D returns.
Faster development. Better use of resources. Shorter cycle times. Higher technical and clinical success rates. More efficient trials. More disciplined execution.
All of these matter. But I think there is a broader question leadership teams need to ask: Are we improving R&D productivity—or are we improving the economics of R&D? The two are related, but they are not the same.
A R&D organization can become more productive and still struggle to generate attractive returns from its innovation/ research investments. Why? Because R&D profitability depends on more than how efficiently a program moves through development.
It depends on:
- what we choose to invest in
- how much we invest
- how long we continue investing
- the probability of creating a differentiated product
- the commercial value that product can capture and
- how effectively resources are allocated across the portfolio.
A program delivered faster and at lower cost is certainly more productive. But if it addresses a limited opportunity, enters an increasingly crowded market, lacks meaningful differentiation, or requires disproportionate downstream investment, greater development efficiency may not translate into greater economic value. That distinction matters...
For executive teams, the conversation therefore needs to move beyond “How do we make R&D more efficient?” to “How do we make R&D a better-performing investment?”
That requires connecting decisions that are often managed separately: portfolio strategy, development economics, evidence generation, resource allocation, product differentiation, and commercial potential.
The objective should not be productivity or profitability. It should be a R&D system where better science, better execution, and better investment decisions reinforce one another.
For Pharma and MedTech leaders facing increasing pressure on innovation returns, I believe this distinction is becoming increasingly important.
Improving how R&D operates is valuable. Improving the return on what R&D invests in is ultimately what creates enterprise value.
For leadership teams examining R&D performance, this may be a useful place to start: Are your productivity initiatives actually changing the economics of the portfolio? Is your R&D organization becoming more efficient—or is it also becoming a better-performing investment?
I work on questions at the intersection of R&D strategy, portfolio economics, and operating performance. Let’s discuss how these can work together to improve your R&D returns.
Disclaimer: This article reflects observed industry trends and professional perspectives and does not constitute regulatory, legal, or operational advice. Read full disclaimer here.
About the author:
Dr. Shruti Bhat is an Advisor in Operational Excellence and Business Continuity Across Pharma and MedTech Value Chains (end-to-end).
Keywords and Tags:
#Pharma #MedTech #RDStrategy #RDProductivity #PortfolioStrategy #Innovation #LifeSciences #CapitalAllocation
Categories: Operational Excellence | Life Science Industry | Pharma R&D
Follow Shruti on YouTube, LinkedIn
About the author:
Dr. Shruti Bhat is an Advisor in Operational Excellence and Business Continuity Across Pharma and MedTech Value Chains (end-to-end).
Keywords and Tags:
#Pharma #MedTech #RDStrategy #RDProductivity #PortfolioStrategy #Innovation #LifeSciences #CapitalAllocation
Categories: Operational Excellence | Life Science Industry | Pharma R&D
Follow Shruti on YouTube, LinkedIn
Subscribe to Operational Excellence Academy YouTube channel: |  |
